Navigation Links
AutoImmune Inc. Reports 2009 First Quarter Financial Results
Date:5/7/2009

12,000 20,000 Research and development 42,000 71,000 General and administrative 205,000 188,000 ------- ------- Total costs and expenses 259,000 279,000 ------- ------- Interest income 84,000 9,000 84,000 9,000 ------ ----- Net loss (108,000) (166,000) Net income (loss) attributable to noncontrolling interest 1,000 (4,000) ----- ------ Net loss attributable to AutoImmune Inc ($107,000) ($170,000) ========= ========= Net loss per share - basic ($0.01) ($0.01) ====== ====== Net loss per share - diluted ($0.01) ($0.01) ====== ====== Weighted average common shares outstanding - basic 16,997,205 16,999,623 ========== ========== Weighted average common shares outstanding - diluted 16,997,205 16,999,623 ========== ========== CONDENSED BALANCE SHEET (Unaudited) December
'/>"/>
SOURCE Autoimmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
4. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
6. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
7. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Investor-Edge has initiated coverage ... ONVO), Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics ... (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). ... at: http://investor-edge.com/register . On Wednesday, October ... 0.33%, the Dow Jones Industrial Average declined 0.18%, to ...
(Date:10/30/2014)... 2014 SoundConnect , an ... Office 365 end users the key to turning ... system by adding voice enablement and hybrid audio ... Online, a communication tool that includes presence, instant ... voice, O365 becomes a comprehensive unified communications solution. ...
(Date:10/30/2014)... 30, 2014 Avure Technologies celebrates a year ... newest member of its fleet of high volume High Pressure ... anniversary as we return to PackExpo this year, which is ... Las Vegas,” said Jeff Williams, CEO at Avure. “Sales of ... pleased to be meeting the challenges of market demand for ...
(Date:10/30/2014)... solution to one of the key challenges in the ... of Sussex physicists. , In a paper published today ... Garraway and colleagues show how to make a new ... Quantum technology devices, such as high-precision sensors and specialised ... of atoms. But the methods for trapping these tiny ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... 2011 Bayer HealthCare,s affiliate MEDRAD, Inc. today ... demonstrated a 59 percent relative reduction in target ... patients with peripheral arterial disease (PAD) treated with ... compared to standard balloon angioplasty (POBA). Additionally, for ...
... SAN DIEGO, Nov. 10, 2011 Verenium Corporation (Nasdaq: ... focused on the development and commercialization of high-performance enzymes, ... financial results for the third quarter and nine months ... strong financial and operational progress in the first nine ...
... GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical ... Human Immunodeficiency Virus (HIV) infections, today announced its financial ... GeoVax reported a net loss of $375,852 ... 30, 2011, compared to $644,666 ($0.04 per share) for ...
Cached Biology Technology:Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 2Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 3Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 4Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 2Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 3Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 4Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 5Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 6Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 7Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 8Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 9GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5
(Date:10/29/2014)... as a consequence of chemotherapy will benefit from a ... technology that prevents hair loss. , The research is ... scalp cooling manufacturing company, Paxman Coolers, of Fenay Bridge, ... University of Huddersfield. , The research will be led ... in the pharmacology of cancer treatment, which he will ...
(Date:10/29/2014)... Beaverton, OR) New research presented at the ... in Houston, TX showed for the first time ... in women using a readily available nutritional supplement, ... by Dr. Judith A. Smith, Pharm.D., associate professor ... Sciences at The University of Texas Health Science ...
(Date:10/29/2014)... and environmental, have been blamed for increasing the ... as a family history of schizophrenia, are widely ... gondii , a parasite transmitted by soil, undercooked ... skepticism. , A new study by Gary Smith, ... University of Pennsylvania,s School of Veterinary Medicine, used ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... that died 44,000 years ago in Antarctica have provided ... traditional genetic aging measurements, and suggest those approaches have ... 200 to 600 percent. In other words, a ... 100,000 years old may actually be 200,000 to 600,000 ...
... -- Agricultural soils accumulate trace metals, particularly copper ... wastes (sewage biosolids and manures) and fungicides that are ... for tolerable concentrations of these potentially plant-toxic elements in ... effects of the metals are substantially independent and not ...
... and LAS VEGAS, Nov. 9 CBS Vision, the ... Media Group company, today announced a new research partnership that will ... housed in the MGM Grand Hotel in Las Vegas. , ... one of the county,s leading agencies, will be called Communications ...
Cached Biology News:Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2Additive copper-zinc interaction affects toxic response in soybean 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 3CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 4
Chicken anti-EEA1...
... Buffers are membrane-filtered isotonic and enzyme-free ... and cell-conditioning agents in either Ca2+- ... or Ca2+- and Mg2+-free phosphate-buffered ... cells from support substrates and each ...
Request Info...
Request Info...
Biology Products: